Anchor-shaped cutaneous flap for volume replacement in oncoplastic breast-conserving surgery for a lower non-ptotic breast.

Surg TodayJul 3, 2026 (epub)
Case ReportOncology (Medical)Plastic SurgeryOpen access

Yuko Kijima, Munetsugu Hirata, Yumika Nakazawa et al.

✦ AI-curated · Sources linked

Case in brief

Three Japanese patients with early breast cancer involving the lower pole of small, non-ptotic breasts underwent an innovative oncoplastic technique using an anchor-shaped cutaneous flap. This method involved tumor resection followed by the elevation and suturing of the flap to fill the defect and recreate the inframammary line. The procedure resulted in excellent breast symmetry without postoperative complications.

Diagnostic / clinical pearl

The anchor-shaped cutaneous flap technique effectively addresses volume replacement in breast-conserving surgery for patients with small, non-ptotic breasts, offering a practical alternative to reduction mammoplasty.

Source

PubMed · PMID 42397561Free full text on PubMed Central

Published in Surg Today. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.